Hunan Jingfeng PharmaceuticalLtd Past Earnings Performance
Past criteria checks 0/6
Hunan Jingfeng PharmaceuticalLtd has been growing earnings at an average annual rate of 13.4%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 26% per year.
Key information
13.4%
Earnings growth rate
13.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -26.0% |
| Return on equity | n/a |
| Net Margin | -36.6% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Hunan Jingfeng PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 581 | -213 | 448 | 49 |
| 31 Dec 23 | 657 | -215 | 503 | 53 |
| 30 Sep 23 | 783 | -134 | 581 | 30 |
| 30 Jun 23 | 819 | -130 | 599 | 36 |
| 31 Mar 23 | 835 | -128 | 603 | 36 |
| 31 Dec 22 | 841 | -128 | 607 | 36 |
| 30 Sep 22 | 863 | -208 | 734 | 36 |
| 30 Jun 22 | 900 | -259 | 782 | 32 |
| 31 Mar 22 | 872 | -191 | 733 | 35 |
| 01 Jan 22 | 811 | -164 | 731 | 39 |
| 30 Sep 21 | 501 | -1,130 | 837 | 180 |
| 30 Jun 21 | 627 | -1,123 | 898 | 213 |
| 31 Mar 21 | 691 | -1,042 | 948 | 236 |
| 31 Dec 20 | 878 | -1,069 | 977 | 253 |
| 30 Sep 20 | 1,247 | -664 | 1,002 | 185 |
| 30 Jun 20 | 1,220 | -807 | 1,141 | 193 |
| 31 Mar 20 | 1,357 | -901 | 1,151 | 187 |
| 31 Dec 19 | 1,344 | -883 | 1,188 | 191 |
| 30 Sep 19 | 2,127 | -73 | 1,430 | 153 |
| 30 Jun 19 | 2,293 | 183 | 1,282 | 139 |
| 31 Mar 19 | 2,497 | 191 | 1,459 | 155 |
| 31 Dec 18 | 2,586 | 187 | 1,451 | 156 |
| 30 Sep 18 | 2,682 | 176 | 1,602 | 142 |
| 30 Jun 18 | 2,658 | 170 | 1,553 | 166 |
| 31 Mar 18 | 2,613 | 144 | 1,552 | 125 |
| 31 Dec 17 | 2,584 | 162 | 1,571 | 93 |
| 30 Sep 17 | 2,592 | 276 | 1,424 | 56 |
| 30 Jun 17 | 2,565 | 280 | 1,482 | 0 |
| 31 Mar 17 | 2,594 | 333 | 1,479 | 0 |
| 31 Dec 16 | 2,641 | 340 | 1,528 | 0 |
| 30 Sep 16 | 2,437 | 319 | 1,413 | 0 |
| 30 Jun 16 | 2,478 | 334 | 1,459 | 0 |
| 31 Mar 16 | 2,501 | 323 | 1,519 | 0 |
| 31 Dec 15 | 2,459 | 324 | 1,489 | 0 |
| 30 Sep 15 | 2,155 | 269 | 1,345 | 0 |
| 30 Jun 15 | 2,136 | 266 | 1,367 | 0 |
| 31 Mar 15 | 2,022 | 257 | 1,316 | 0 |
| 31 Dec 14 | 1,957 | 251 | 1,313 | 0 |
| 30 Jun 14 | 1,663 | 186 | 1,131 | 0 |
| 31 Mar 14 | 1,442 | 149 | 981 | 0 |
| 31 Dec 13 | 1,419 | 135 | 970 | 0 |
Quality Earnings: 000908 is currently unprofitable.
Growing Profit Margin: 000908 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000908 is unprofitable, but has reduced losses over the past 5 years at a rate of 13.4% per year.
Accelerating Growth: Unable to compare 000908's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 000908 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 000908's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.